Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. - Wikidata - wikimedia - TriplyDB

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs.

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs.

http://www.wikidata.org/entity/Q43917199

about

Bisphosphonates for osteoporosis in primary biliary cirrhosis Bisphosphonates for osteoporosis in primary biliary cirrhosis European guidance for the diagnosis and management of osteoporosis in postmenopausal women Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspective From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis Ultrasonic bone assessment: "the time has come".Qualitative and quantitative ultrashort-TE MRI of cortical bone.Microindentation for in vivo measurement of bone tissue mechanical properties in humans.Potential Usefulness of BMD and Bone Turnover Monitoring of Zoledronic Acid Therapy Among Women With Osteoporosis: Secondary Analysis of Randomized Controlled Trial Data.Exploring the relationship between surrogates and clinical outcomes: analysis of individual patient data vs. meta-regression on group-level summary statistics.Role of trabecular microarchitecture in whole-vertebral body biomechanical behavior Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data.Effects of Combination Therapy of Alendronate and Hormonal Therapy on Bone Mineral Density in Postmenopausal Korean Women: Multicenter, Randomized Controlled Clinical Trial.The assessment of fracture risk.Combination Therapy of Raloxifene and Alendronate for Treatment of Osteoporosis in Elderly Women.Advances in therapy for osteoporosis.Randomized clinical trial comparing efficacy and safety of brand versus generic alendronate (Bonmax®) for osteoporosis treatment.What old means to bone.The effect of antiresorptives on bone quality.Reduced tissue-level stiffness and mineralization in osteoporotic cancellous bone Effects of suppression of bone turnover on cortical and trabecular load sharing in the canine vertebral body.Effect of sequential treatments with alendronate, parathyroid hormone (1-34) and raloxifene on cortical bone mass and strength in ovariectomized rats.Effects of tissue age on bone tissue material composition and nanomechanical properties in the rat cortex.Evaluation of compressive strength index of the femoral neck in Caucasians and chinese.Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability.Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study.Bisphosphonates for steroid-induced osteoporosis.Estrogens and Androgens in Skeletal Physiology and Pathophysiology.A biomechanical analysis of the effects of resorption cavities on cancellous bone strength Automated registration of hip and spine for longitudinal QCT studies: integration with 3D densitometric and structural analysis.The Effect of Osteoporosis Treatments on Fatigue Properties of Cortical Bone Tissue.Biochemical markers for assessment of calcium economy and bone metabolism: application in clinical trials from pharmaceutical agents to nutritional products.Effects of D-003 (10 mg/day) on bone mineral density of the lumbar spine and femoral neck in postmenopausal women: a randomized, double-blinded study.Management of primary osteoporosis.Biochemical markers of bone turnover part II: clinical applications in the management of osteoporosis Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids Microstructural, densitometric and metabolic variations in bones from rats with normal or altered skeletal states.Diseases affecting bone quality: beyond osteoporosis.Microstructure and nanomechanical properties in osteons relate to tissue and animal age.Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study.

P2860

Q24234283-A542ACEB-52DA-475D-A4E1-D955E6679D25 Q24234967-F4FE3028-57A8-4DC7-A7AE-E9A4DF2B2DC6 Q24612411-E5B1B7F7-BBE3-42D3-B42C-F029FD6AB1C7 Q26864207-4EB9D4E2-C37B-4486-9787-1F8F0748058F Q28385120-C06A26C3-B389-4C1D-A411-7670EDB468F1 Q30494467-E58EFA4B-1337-49F5-98EE-4FE961B089F3 Q30583890-5A50AD6B-B58A-4C00-9610-D4C683BAFDD5 Q30979077-4C7D4FFE-3EB1-4980-BB40-884AFAA9B536 Q31065032-C7FDDF35-4265-4B21-85CD-5EBA1F190291 Q33194319-7A87F4C7-8E90-4758-AC2E-F2BEE4C00FE6 Q33425431-C9ED18E2-3B96-42B1-8C7F-1E13E7FB924F Q33473097-8E1B3D6F-B599-4436-9065-9CEF5AD95060 Q33661422-3D6F89C1-D3F2-4E2B-9E47-8707253B4E92 Q33685092-BB75C829-1FEC-4C4B-A9C2-DAF3DB4AFE55 Q33689384-655CF754-6CBF-400D-8C18-1805FA9CB89C Q33723337-02AEE50D-A136-4F88-8D4D-C530F3EE0D7E Q33874055-DA21F649-7342-47A8-A52F-D8B7F256EFE8 Q33892053-C3CFAE12-56F8-4008-ADC6-8C5C5F9204B2 Q33896122-4D0B7139-AE80-4937-BFF8-9179F144C38C Q33923122-111D28EF-AAC5-4E52-8BF0-B7D62B9DE1FC Q33923777-B7A0DB0A-C61B-4AD0-8417-2FB9084EF78E Q34149279-3435D8AD-C875-4100-8F3E-2CDF3265E8E7 Q34159899-633D2B56-2116-4A1B-BCC8-395C6F6A7546 Q34252375-670C6512-00C1-4EAC-A493-540522851D25 Q34367479-A8FCCCA8-0F6F-427C-9492-60AC174D9BE1 Q34439029-ABA552CE-CB82-448F-A031-72AFD165D008 Q34542004-163D6A6A-5E72-4C95-905A-4F83E727FD9E Q34543980-55D281C5-FD61-4F38-8FE2-302C9B413825 Q34551219-2B5C92DF-85AD-465F-93CB-FB6049AA0349 Q34997596-3C71B42F-8644-4FAC-B540-8FA5C88FAAAA Q35012189-061B0ADF-5032-46B0-B1B0-32F7A16B1F3B Q35017714-D4EE89D5-2274-4F2B-8E1F-56363D2D27C7 Q35033570-8D569EAD-90F7-44F8-82CD-847E6894E543 Q35047919-E5037C1A-1575-4556-A6A8-0D0CC61CBA35 Q35053491-A2194CD5-2336-44D1-83A0-E374DD4C30F5 Q35058081-59CDD3B2-375D-4BBE-9A3C-100957C23451 Q35072881-5C9E54E2-F847-42A1-B071-1C426230BF85 Q35078847-226A1FFC-492C-473D-B13E-7CA2EEA3B2C0 Q35084410-36714B92-1D56-4A1A-A320-ED4D950EE00B Q35215353-FAC49ADB-903C-4B22-A803-459F43D48BC0

P2860

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs.

http://www.wikidata.org/entity/Q43917199

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Improvement in spine bone dens ...... ent with antiresorptive drugs.

@en

Improvement in spine bone dens ...... ent with antiresorptive drugs.

@nl

type

label

Improvement in spine bone dens ...... ent with antiresorptive drugs.

@en

Improvement in spine bone dens ...... ent with antiresorptive drugs.

@nl

prefLabel

Improvement in spine bone dens ...... ent with antiresorptive drugs.

@en

Improvement in spine bone dens ...... ent with antiresorptive drugs.

@nl

P1433

Q43917199-A008D35F-674A-4E32-8E60-AD113B21B118

P1476

Q43917199-8701164D-D6EE-46DB-B123-0820E38C19A0

P2093

Q43917199-0EA587D7-C895-46E2-9411-D90E176B9111

Q43917199-148513A0-37C6-46B0-B83B-447F7E395CD7

Q43917199-214A4107-1126-4FA2-854C-0A16230874D7

Q43917199-C213B5B3-FF1F-416D-828B-2BA76658391A

Q43917199-F4C9218E-E039-4910-926D-B436E12EAC9F

Q43917199-F81BEB7A-74BB-4D7A-8685-076450FCF9C1

Q43917199-FFE204E5-CB22-4037-BFDA-3E31B51CB04E

P304

Q43917199-9C7B3F44-36E4-4829-935E-6A26D0B4A134

P31

Q43917199-3E75B380-D76E-4A4C-897B-BEFA6EFD6A01

Q43917199-f916fc88-13de-47c7-92b2-6ebd64eedd0a

P356

Q43917199-4779FDD4-1DD4-4AC3-858A-9BCE3168F5FF

P407

Q43917199-397FA54C-3CBC-4AA9-A2DE-3890B87F9511

P433

Q43917199-C5498C10-6EC7-42F9-AB00-5359B54825D8

P478

Q43917199-00FFE311-F07C-47BD-8306-FB674995C5C7

P577

Q43917199-6D78ED64-69C2-43D6-91AD-C1250CF6C4CC

P698

Q43917199-5FB4BE2C-886B-4107-A230-2E5461322CA4

P356

S0002-9343(01)01124-X

P1433

The American Journal of Medicine

P1476

Improvement in spine bone dens ...... ent with antiresorptive drugs.

@en

P2093

Andrea Z LaCroix

http://www.w3.org/2001/XMLSchema#string

David B Karpf

http://www.w3.org/2001/XMLSchema#string

Dennis M Black

http://www.w3.org/2001/XMLSchema#string

Fran Harris

http://www.w3.org/2001/XMLSchema#string

Harry K Genant

http://www.w3.org/2001/XMLSchema#string

Kristine Ensrud

http://www.w3.org/2001/XMLSchema#string

Steven R Cummings

http://www.w3.org/2001/XMLSchema#string

P304

281-289

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0002-9343(01)01124-X

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P577

2002-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11893367

http://www.w3.org/2001/XMLSchema#string